Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs Thomson Reuters Corp — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.18B), while Thomson Reuters Corp trades at $106.46 (market cap $45.37B). The key difference: Thomson Reuters Corp is far larger — about 10.9× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Thomson Reuters Corp pays a 2.49% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Thomson Reuters Corp for 63 Days on average.
| INDV | TRI | |
|---|---|---|
Market Cap | $4.18B | $45.37B |
Volume | 1,819,746 | 729,201 |
Sector | Health | Industrials |
52-Week High | $41.83 | $163.45 |
52-Week Low | $24.09 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $4.47B | $47.98B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) trades at $105.40, up 1.1% today, with a bullish technical outlook and strong analyst support. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while maintaining robust profitability with a 21.22% net income margin. Recent strategic moves include divesting its Global Print business to focus on technology and launching a proprietary AI model, reinforcing its competitive edge in legal and tax solutions.
The stock offers upside to the consensus price target of $128.60, supported by recurring revenue growth and AI expansion, but faces risks from cybersecurity incidents and integration challenges from recent divestitures. Valuation multiples like a P/E of 27.69 suggest premium pricing, requiring sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
